Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation

This article was originally published in The Tan Sheet

Executive Summary

A youth sports advocacy group is attempting to halt the sale and use of androstenedione-containing dietary supplements with a dual-pronged initiative aimed at Major League Baseball players and federal regulators, including FDA.

You may also be interested in...



Sports Supplement Steroid Metabolites Targeted By AMA

The American Medical Association will urge Congress to develop and enact legislation declaring anabolic steroid metabolites and precursors as drug substances not suitable for use in dietary supplements.

Sports Supplement Steroid Metabolites Targeted By AMA

The American Medical Association will urge Congress to develop and enact legislation declaring anabolic steroid metabolites and precursors as drug substances not suitable for use in dietary supplements.

Sports Supplement Steroid Metabolites Targeted By AMA

The American Medical Association will urge Congress to develop and enact legislation declaring anabolic steroid metabolites and precursors as drug substances not suitable for use in dietary supplements.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel